Allspring Global Investments Holdings LLC Has $1.32 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) by 74.6% in the third quarter, HoldingsChannel reports. The firm owned 69,101 shares of the company’s stock after selling 203,237 shares during the period. Allspring Global Investments Holdings LLC’s holdings in iTeos Therapeutics were worth $1,316,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ITOS. BlackRock Inc. increased its holdings in iTeos Therapeutics by 106.5% during the 1st quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock valued at $107,203,000 after purchasing an additional 1,718,085 shares in the last quarter. State Street Corp increased its holdings in iTeos Therapeutics by 124.3% during the 1st quarter. State Street Corp now owns 1,711,891 shares of the company’s stock valued at $55,089,000 after purchasing an additional 948,540 shares in the last quarter. Vanguard Group Inc. boosted its position in iTeos Therapeutics by 39.1% in the 1st quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock valued at $47,499,000 after buying an additional 415,232 shares during the last quarter. JPMorgan Chase & Co. boosted its position in iTeos Therapeutics by 146.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company’s stock valued at $11,522,000 after buying an additional 332,625 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in iTeos Therapeutics by 276.9% in the 2nd quarter. AQR Capital Management LLC now owns 445,110 shares of the company’s stock valued at $9,169,000 after buying an additional 327,025 shares during the last quarter.

iTeos Therapeutics Stock Performance

Shares of ITOS opened at $21.70 on Friday. The firm has a market capitalization of $771.98 million, a price-to-earnings ratio of 3.15 and a beta of 1.38. The business’s fifty day moving average price is $19.76 and its two-hundred day moving average price is $21.06. iTeos Therapeutics, Inc. has a 52 week low of $16.21 and a 52 week high of $38.14.

iTeos Therapeutics (NASDAQ:ITOSGet Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. The company had revenue of $19.49 million during the quarter, compared to the consensus estimate of $42.05 million. As a group, research analysts forecast that iTeos Therapeutics, Inc. will post 2.85 EPS for the current year.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

See Also

Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating).

Institutional Ownership by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.